RCKT Rocket Pharmaceuticals Inc.

17.19
-0.42  -2%
Previous Close 17.61
Open 17.62
Price To book 11.16
Market Cap 29247444
Shares 1,701,422
Volume 210,659
Short Ratio 0.86
Av. Daily Volume 300,962

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma